Blocking Cancer Cells' Don't Eat Me Signal Shows Promise as a New Treatment for Metastatic Gastric Cancer
AI 요약 정보
- Evorpacept-trastuzumab tested in metastatic gastric cancer
- Response rate: 40.3% with combo vs 26.6% with control
- HER2+/high-CD47 cases: combo response 63.6%; control 23.1%